Proxibarbital

Proxibarbital
Clinical data
Other names	Proxibarbal, Proxibarbitone, Centralgal, Ipronal, 5-Allyl-5-(β-hydroxypropyl)barbituric acid
ATC code	N05CA22 (WHO) ;
Identifiers
	IUPAC name (RS)-5-allyl-5-(2-hydroxypropyl)pyrimidine-2,4,6(1H,3H,5H)-trione;
CAS Number	2537-29-3 ;
PubChem CID	17336;
ChemSpider	16406 ;
UNII	F97OMS297F;
ChEMBL	ChEMBL2105233;
CompTox Dashboard (EPA)	DTXSID20862980 ;
ECHA InfoCard	100.018.004
Chemical and physical data
Formula	C10H14N2O4
Molar mass	226.232 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1NC(=O)NC(=O)C1(CC(O)C)C\C=C;
	InChI InChI=1S/C10H14N2O4/c1-3-4-10(5-6(2)13)7(14)11-9(16)12-8(10)15/h3,6,13H,1,4-5H2,2H3,(H2,11,12,14,15,16) ; Key:VNLMRPAWAMPLNZ-UHFFFAOYSA-N ;
	(what is this?) (verify)

Proxibarbital (Ipronal) is a barbiturate derivative synthesized in 1956 in Poland by Bogusław Bobrański. It has anti-anxiety and sedative properties and is, in contrast to most barbiturates, almost without hypnotic action.^[1] It was used as a sedative and anti-anxiety drug. It was also used in the treatment of migraine headaches in a similar manner to butalbital.^[2] It was a prescription drug available in Poland from the 1950s to the 1990s under trade name Ipronal.